|Awarded On||February 16, 2022|
|Title||Evolution of small-cell lung cancer from the normal airway|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Paul Scheet|
|Cancer Sites||Lung and Bronchus|
Ninety million former and current smokers in the United States (U.S.) are at elevated risk for lung cancer, the leading cause of cancer deaths in Texas, the U.S. and worldwide. Small-cell lung cancer (SCLC) occurs almost exclusively in smokers, and is particularly deadly with a mere 7% overall survival rate. This dismal outcome is attributed to late-stage diagnosis, and has exhibited little progress in treatment in the past decades. Knowledge of critical molecular events early in SCLC development is lacking. Such events may serve as biomarkers to aid in earlier detection, inform our understanding of how SCLC initiates and progresses, and comprise targets for personalized treatment. We and ot...